<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2777">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04252274</url>
  </required_header>
  <id_info>
    <org_study_id>DC-COVID-19</org_study_id>
    <nct_id>NCT04252274</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19</brief_title>
  <acronym>DC-COVID-19</acronym>
  <official_title>Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Public Health Clinical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Public Health Clinical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to evaluate the efficacy and safety of darunavir and cobistastat in the
      treatment of COVID-19 pneumonia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is no vaccine or antiviral treatment for human coronavirus, so this study aims to
      evaluate the efficacy and safety of darunavir and cobistastat in the treatment of COVID-19
      pneumonia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 30, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 7</measure>
    <time_frame>7 days after randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 3</measure>
    <time_frame>3 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The virological clearance rate of throat swabs, sputum, or lower respiratory tract secretions at day 5</measure>
    <time_frame>5 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>14 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The critical illness rate of subjects at weeks 2</measure>
    <time_frame>14 days after randomization</time_frame>
    <description>The diagnosis of critical illness case was based on the notice on printing and distributing the diagnosis and treatment plan of pneumonia with new coronavirus infection (trial version 4) made by National Health Commission of the People's Republic of China.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The mortality rate of subjects at weeks 2</measure>
    <time_frame>14 days after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pneumonia, Pneumocystis</condition>
  <condition>Coronavirus</condition>
  <arm_group>
    <arm_group_label>Darunavir, Cobicistat and conventional treatments</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After randomization, subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional treatments</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After randomization, subjects take conventional treatments without darunavir and cobicistat.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir and Cobicistat</intervention_name>
    <description>Subjects take darunavir and cobicistat one tablet per day for 5 days, also take conventional treatments</description>
    <arm_group_label>Darunavir, Cobicistat and conventional treatments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The participants were diagnosed as COVID-19 pneumonia, according to the notice on
             printing and distributing the diagnosis and treatment plan of pneumonia with new
             coronavirus infection (trial version 4 or update version) made by National Health
             Commission of the People's Republic of China.

          -  Written the informed consent

        Exclusion Criteria:

          -  Hypersensitivity to darunavir, cobicistat, or any excipients

          -  Patients with severe liver injury (Child-Pugh Class C)

          -  Concomitant medications that are highly dependent on CYP3A clearance, and the elevated
             plasma concentrations are associated with serious or life-threatening events.

          -  Subjects were considered to be unable to complete the study, or not suitable for the
             study by researchers

        Exit criteria:

          -  Subjects asked to withdraw the study

          -  Subject will benefit if withdraw according to researchers' suggestions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongzhou Lu, Ph.D</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hongzhou Lu, PI</last_name>
    <phone>+86-021-37990333</phone>
    <phone_ext>3222</phone_ext>
    <email>luhongzhou@fudan.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhou Lu</last_name>
      <phone>008602137990333</phone>
      <phone_ext>3222</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Public Health Clinical Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongzhou Lu, PI</last_name>
      <phone>+86-021-37990333</phone>
      <phone_ext>3222</phone_ext>
      <email>luhongzhou@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 29, 2020</study_first_submitted>
  <study_first_submitted_qc>January 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>April 9, 2020</last_update_submitted>
  <last_update_submitted_qc>April 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Public Health Clinical Center</investigator_affiliation>
    <investigator_full_name>Hongzhou Lu</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Cobicistat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Pneumocystis</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

